Avella Specialty Pharmacy announced that it has purchased Oncology Plus, LLC, a leading provider of patient-specific compounded therapies to oncology practices, hospitals and payors nationwide.
With this acquisition, Avella furthers its strategic vision of becoming the leading omni-site specialty pharmacy in the nation and adds to the breadth of its compounding and oncology-focused capabilities and services.
Oncology Plus, LLC, headquartered in Tampa, Florida, provides custom, unit dose, patient-specific chemotherapy drugs used in IV or other specialized administration for the treatment of hematology/oncology patients in the hospital or practice setting. Oncology Plus maintains a state-of-the-art, 5,000-square-foot USP800 compliant facility and leverages Logics+, its proprietary ordering, dosing and pathway compliance software, to ensure best in class patient care, safety, quality and outcomes.
Avella offers breakthrough specialty and compounded medications used for the treatment of serious health conditions, such as cancer, hepatitis C and HIV, among others. With the acquisition of Oncology Plus, Avella's oncology offerings now span across multiple sites of care including physician office, retail and hospital and includes both compounded and oral therapies. Avella also serves hospitals and health systems through the company's robust 340B drug discount program. In addition, the organization just announced its agreement to purchase Advanced Pharma, a Texas-based provider of sterile IV drugs for hospitals.
"We are very excited to become part of a specialty pharmacy with such a strong reputation for clinical excellence and high-quality compounding," said Zach Scholl, president of Oncology Plus. "Avella's national footprint, industry relationships and expertise in the oncology space, combined with the IV compounding capabilities of Oncology Plus, will uniquely position us as a leader in this marketplace."
Oncology Plus, which will be rebranded as part of Avella, maintains a strong commitment to excellence in quality and customer service. The organization also shares Avella's high standards for patient safety, illustrated by Oncology Plus' maintenance of USP 800 compliance, PCAB Accreditation and reliance on high-tech patient ordering, dosing and pathway compliance software. These capabilities made the opportunity to purchase Oncology Plus particularly attractive to Avella's leadership.
According to Avella CEO Rebecca M. Shanahan, "Oncology Plus is dedicated to providing unsurpassed value to its customers while ensuring the highest levels of quality and safety. This aligns perfectly with Avella's own high standards for our business. As a result, the move to integrate the people and products of Oncology Plus within our own compounding capabilities will give us greater scale and unique capabilities to service all of the pharmacy outsourcing needs of our practice and hospital partners."